News
Public · Published
B of A Securities maintains Regeneron Pharmaceuticals at Buy, raises price target to $1030 from $908
B of A Securities kept its Buy rating on Regeneron Pharmaceuticals and raised its price target to $1030 from $908. The new target is a 13.4% increase and implies 11.0% upside from the October 30 closing price of $927.89.
Published:
Updated:
What happened
B of A Securities kept its Buy rating on Regeneron Pharmaceuticals and raised its price target to $1030 from $908. The new target is a 13.4% increase and implies 11.0% upside from the October 30 closing price of $927.89.
Confirmed
Global impact / market context
A higher target signals that B of A Securities sees more potential value in Regeneron shares, but it is an analyst estimate, not a company forecast or guaranteed return. Investors may use it when weighing expected share gains against the possibility that the estimate proves too optimistic.
Analyst inference
Recent analyst targets span $825 to $1050, with ratings ranging from Neutral to Buy and Overweight. That spread shows analysts disagree on Regeneron’s value; the raised target sits within the range, so it does not establish a shared view of the company’s prospects.
Confirmed
What to watch
- Compare future analyst targets and ratings with this $1030 target; widening disagreement could make investor expectations less settled, while convergence would indicate a more consistent view. Analyst inference
- Check whether Regeneron reports company updates that explain changes in expected revenue or costs; the article provides no business results or operating outlook behind the target increase. Analyst inference
- The article states the target implies 11.0% upside from the October 30 close of $927.89; this comparison is based on that closing price. Confirmed
Evidence
- Original source link unavailable